Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 2
Initial Study Sesting Efficacy and Tolerability of PT150 for PTSD in Veterans
Key facts
- Who runs it
- San Diego Veterans Healthcare System
- Where
- Houston and San Diego, United StatesSee the 2 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 120 people, planned
- Started
- 1 Apr 2026
- Expected to end
- 1 May 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- PT150
- Placebo
- Record updated
- 23 December 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Provide signed and dated informed consent form
- Be a military service member or Veteran
- Male or female, 18-65 years of age
- Meet DSM-5 criteria for PTSD ≥ 3 months duration as determined by CAPS-5
- Normal vitals and a baseline EKG with clinically normal sinus rhythm, clinically normal conduction, normal QTc, and no clinically significant arrhythmias
- Self-reported medical history and brief physical examination with no clinically significant contraindications for study participation
- Blood laboratory test results for routine hematology, chemistries, liver and kidney function tests within acceptable limits
- Willing to comply with all study procedures including taking oral medication, the study schedule and be available for the duration of the study Biological females, if able to conceive, must agree to use 2 forms of non-hormonal, medically acceptable contraception
Who cannot take part
- History or diagnosis of neurodegenerative disorders, psychotic disorders or bipolar disorder. Current treatment with antipsychotic medication for mental health
- Currently using psychotropic medication (except SSRI/SNRI) or other drugs or agents which might interact with study drug. Currently taking SSRI/SNRI antidepressants for less than 30 days. Benzodiazepines or sleep agents (e.g. eszopiclone; zolpidem) are excluded; exception: trazodone 25-50 mg qhs prn for sleep or prazosin for nightmares
- Receiving non-pharmacotherapy treatments or procedures for where precautions exist for taking with PT150 and/or those that might interfere with the study
- Participation in a pharmaceutical trial or use of investigational drugs within 1 month of screening
- Severe alcohol or substance use disorders by DSM-5 criteria in past 3 months or positive urine test for substances other than cannabis
- History of suicide attempts and/or current suicidal ideation with plan or intent
- Evidence of a serious, chronic medical condition that would increase the risk of an adverse outcome or history of any serious metabolic or other disease known to affect the CNS
- Have evidence of untreated or unstable medical illness including cardiovascular, neuroendocrine, autoimmune, renal, hepatic, or active HIV+/AIDS infection
- Serious cognitive impairment likely to interfere with ability to meaningfully participate
- A history of adrenal insufficiency or a plasma cortisol level ≤ 5 mcg/dl at screening
- Contraindication(s) to take PT150 such as renal or hepatic impairment, congenital metabolic disorders, or hypersensitivity to study drug or similar compounds
- Any other illness, condition, or use of medications which in the opinion of the PI and/or study investigator would preclude safe and/or successful completion of the study
- Be pregnant or nursing
- HRT dose not stable for a minimum of 3 months
- Past brain injury/head trauma with minor loss of consciousness and current symptoms or significant loss of consciousness
- Current signs of violence or aggression
- Hearing loss that would interfere with the extinction recall measures
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Michael E. DeBakey VA Medical CenterHouston, United StatesContact: Giovanni Castillo, BSNot yet recruiting
- Jennifer Moreno Department of VA Medical CenterSan Diego, United StatesContact: Giovanni Castillo, BSNot yet recruiting
About the trial
What the trial wants to find out
The purpose of this study is to test the drug PT150, which blocks glucocorticoid receptor (GR) signaling, for treatment of PTSD in Veterans, and establish a safety and efficacy profile that will inform the design of future studies.
The 2 groups in the trial
- PlaceboPlacebo, for comparison
- PT150Treatment being tested
150-900 mg study drug dose titrated over 7 days
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 2a Trial: Efficacy and Safety of PT150 in the Treatment of US Veterans With Posttraumatic Stress Disorder (PTSD)
- Criteria questions
- Built from NCT07187011, who can take part
- Record updated
- 23 December 2025